Saad Z Usmani

Saad Z Usmani

UNVERIFIED PROFILE

Are you Saad Z Usmani?   Register this Author

Register author
Saad Z Usmani

Saad Z Usmani

Publications by authors named "Saad Z Usmani"

Are you Saad Z Usmani?   Register this Author

78Publications

2884Reads

20Profile Views

Extramedullary multiple myeloma.

Leukemia 2019 Nov 27. Epub 2019 Nov 27.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0660-0DOI Listing
November 2019

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.

Front Immunol 2018 20;9:2134. Epub 2018 Sep 20.

Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC, United States.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fimmu.2018.02134
Publisher Site
http://dx.doi.org/10.3389/fimmu.2018.02134DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158369PMC
October 2019

Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.

Leuk Lymphoma 2019 Sep 8;60(9):2295-2298. Epub 2019 Mar 8.

Department of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute , Charlotte , NC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1576871DOI Listing
September 2019

Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.

Br J Haematol 2019 Jul 11;186(1):140-144. Epub 2018 Dec 11.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15716DOI Listing
July 2019

Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.

J Oncol Pharm Pract 2019 Jun 26;25(4):1021-1025. Epub 2018 Nov 26.

2 Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155218815305DOI Listing
June 2019

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

N Engl J Med 2019 05;380(22):2104-2115

From University of Lille, Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, Lille (T.F.), Hematology Department, University Hospital Hôtel-Dieu, Nantes (P.M.), Department of Hematology, Hospital Haut Leveque, University Hospital, Pessac (C.H.), Hematology Department, University Hospital, Vandoeuvre lès Nancy (A.P.), Service d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse (M.A.), Department of Hematology, Vendée Hospital, La Roche sur Yon (M.T.), CHU de Caen, Caen (M.M.), Department of Clinical Hematology, Assistance Publique-Hôpitaux de Paris, Necker Hospital, Paris (L.F.), and Department of Hematology, CHU la Miletrie and INSERM CIC 1402, Poitiers (X.L.) - all in France; the Department of Hematology, Mayo Clinic Rochester, Rochester, MN (S.K.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.); Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); University of Calgary, Arnie Charbonneau Cancer Research Institute, Calgary, AB (N.B.), and the Division of Medical Oncology, University of Alberta, Edmonton (C.P.V.) - both in Canada; Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom (S.B.); Karolinska Institute, Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia (H.Q.); University Hospital Heidelberg and National Center of Tumor Diseases (NCT), Heidelberg (H.G.), and the Department of Oncology, Hematology and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (K.W.) - both in Germany; Department of Medicine-Haematology, National University of Ireland, Galway (M.O.); Florida Cancer Specialists and Research Institute, St. Petersburg (J.R.M.); the Department of Hematology-Oncology, Massachusetts General Hospital, Boston (N.R.); Genmab US, Princeton (T.A.), and Janssen Research and Development, Raritan (J.W., R.K.) - both in New Jersey; Janssen Research and Development, Spring House, PA (C.C., C.M.U., M.Q.); Janssen Research and Development, Beerse, Belgium (R.V.R.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1817249
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1817249DOI Listing
May 2019

Induction Therapy for Newly Diagnosed Multiple Myeloma.

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:e176-e186. Epub 2019 May 17.

4 Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_238527DOI Listing
January 2019

Treatment approach for young, fit, newly diagnosed multiple myeloma patients.

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):97-102

Johns Hopkins University School of Medicine, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.97DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246032PMC
November 2018

Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.

Drug Des Devel Ther 2017 20;11:893-900. Epub 2017 Mar 20.

Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Carolinas Healthcare System, UNC School of Medicine, Charlotte, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DDDT.S98053DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367738PMC
May 2017

Practical Considerations in Managing Relapsed Multiple Myeloma.

Clin Lymphoma Myeloma Leuk 2017 02 23;17(2):69-77. Epub 2016 Nov 23.

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.11.010DOI Listing
February 2017

Maintenance lenalidomide after transplantation: How much is enough?

Authors:
Saad Z Usmani

Cancer 2016 12 28;122(24):3762-3764. Epub 2016 Sep 28.

Levine Cancer Institute/Carolinas Healthcare System, Charlotte, North Carolina.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30363DOI Listing
December 2016

The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.

Expert Rev Hematol 2016 Dec 14;9(12):1177-1187. Epub 2016 Nov 14.

a Department of Hematologic Oncology and Blood Disorders , Levine Cancer Institute/Carolinas HealthCare System , Charlotte , NC , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2016.1254545DOI Listing
December 2016

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

N Engl J Med 2016 10;375(14):1319-1331

From the National and Kapodistrian University of Athens, Athens (M.A.D.); Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias I Pujol, Barcelona (A.O.), and Clínica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Karolinska Institute and the Department of Medicine, Division of Hematology, Karolinska University Hospital at Huddinge, Stockholm (H.N.); Tom Baker Cancer Centre, University of Calgary, Calgary, AB (N.J.B.), and the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto (D.R.) - both in Canada; Levine Cancer Institute-Carolinas HealthCare System, Charlotte, NC (S.Z.U.); the Department of Haematology, University College London Hospitals NHS Trust, London (N.R.); the Department of Lymphoma-Myeloma, University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); the Department of Hematology and Stem Cell Transplantation, Poznan University of Medical Sciences, Poznan, Poland (M.K.); the Department of Hematology, Japanese Red Cross Medical Center, Tokyo (K.S.); Vejle Hospital and University of Southern Denmark, Vejle (T.P.), and Genmab, Copenhagen (S.L.) - both in Denmark; the Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea (S.-S.Y.); the Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem (D.B.Y.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (P.G.R.); University Hospital Heidelberg and the German Cancer Research Center, Heidelberg, Germany (H.G.); Janssen Research and Development, Spring House, PA (N.Z.K., L.O., C.C., X.Q., M.G., T.A.); and the Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France (P.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607751DOI Listing
October 2016

The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.

Clin Adv Hematol Oncol 2016 Sep;14(9):719-28

Levine Cancer Institute of the Carolinas HealthCare System, Charlotte, North Carolina.

View Article

Download full-text PDF

Source
September 2016

Cutaneous manifestations of multiple myeloma and other plasma cell proliferative disorders.

Semin Oncol 2016 06 23;43(3):395-400. Epub 2016 Feb 23.

Plasma Cell Disorders Program, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.02.017DOI Listing
June 2016

Successful Treatment of Hepatitis C Infection While Receiving Concurrent Chemotherapy for AL Amyloidosis.

Clin Lymphoma Myeloma Leuk 2016 Apr 18;16(4):237-9. Epub 2016 Jan 18.

Department of Hematologic Oncology and Blood Disorders, Carolinas HealthCare System, Levine Cancer Institute, Charlotte, NC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.01.003DOI Listing
April 2016

Multiple myeloma: is it time for biomarker-driven therapy?

Am Soc Clin Oncol Educ Book 2015 :e493-503

From the Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute/Carolinas Healthcare System, Charlotte, NC; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e493DOI Listing
February 2016

Fulminant onset of acute leukemia from normal hematopoiesis within 3 months of follow up for multiple myeloma treated with total therapy protocols.

Clin Case Rep 2015 Mar 13;3(3):183-92. Epub 2015 Feb 13.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences 4301 West Markham Slot 816, Little Rock, Arkansas, 72205.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ccr3.180
Publisher Site
http://dx.doi.org/10.1002/ccr3.180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4377252PMC
March 2015

Novel drug combinations for the management of relapsed/refractory multiple myeloma.

Clin Lymphoma Myeloma Leuk 2014 Sep;14 Suppl:S71-7

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2014.06.016DOI Listing
September 2014

Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.

Clin Lymphoma Myeloma Leuk 2014 Jun 16;14(3):211-4. Epub 2013 Nov 16.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2013.11.004DOI Listing
June 2014

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.

PLoS One 2013 16;8(9):e74191. Epub 2013 Sep 16.

Myeloma Institute for Research and Therapy, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0074191PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3774816PMC
May 2014

Management of relapses after hematopoietic cell transplantation in T-cell non-Hodgkin lymphomas.

Semin Hematol 2014 Jan 15;51(1):73-86. Epub 2013 Nov 15.

Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute and University of South Florida College of Medicine, Tampa, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2013.11.005DOI Listing
January 2014

Waldenström's macroglobulinemia associated with serum amyloid A protein amyloidosis: pitfalls in diagnosis and successful treatment with melphalan-based autologous stem cell transplant.

Acta Haematol 2013 9;130(3):146-9. Epub 2013 May 9.

Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Ark., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000347036DOI Listing
December 2013

Molecular chaperone gp96 is a novel therapeutic target of multiple myeloma.

Clin Cancer Res 2013 Nov 27;19(22):6242-51. Epub 2013 Sep 27.

Authors' Affiliations: Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina; Levine Cancer Institute, Charlotte, North Carolina; Department of Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York; and The University of Texas MD Anderson Cancer Center, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-2083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3851294PMC
November 2013

Melphalan continues to rock the myeloma world.

Authors:
Saad Z Usmani

Biol Blood Marrow Transplant 2013 May 24;19(5):680-1. Epub 2013 Feb 24.

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2013.02.014DOI Listing
May 2013

Thalidomide and its analogues in the treatment of Multiple Myeloma.

Exp Hematol Oncol 2012 Sep 11;1(1):27. Epub 2012 Sep 11.

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, 4301 W, Markham Street, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2162-3619-1-27DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514107PMC
September 2012

HSP90 inhibitors as therapy for multiple myeloma.

Clin Lymphoma Myeloma Leuk 2011 Jun 28;11 Suppl 1:S77-81. Epub 2011 Apr 28.

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AZ 72205, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S215226501100041
Publisher Site
http://dx.doi.org/10.1016/j.clml.2011.03.027DOI Listing
June 2011

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.

J Hematol Oncol 2010 Oct 26;3:40. Epub 2010 Oct 26.

Myeloma Institute for Research & Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-8722-3-40DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974653PMC
October 2010

Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era.

Asian Pac J Cancer Prev 2009 ;10(6):1039-40

Division of Hematology-Oncology, University of Connecticut Health Center, Farmington, CT 06030, USA.

View Article

Download full-text PDF

Source
September 2010

17 AAG for HSP90 inhibition in cancer--from bench to bedside.

Curr Mol Med 2009 Jun;9(5):654-64

Division of Hematology-Oncology, Lea Foundation's Center for Hematologic Disorders, Carole & Ray Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/156652409788488757DOI Listing
June 2009

Duodenal MALT lymphoma presenting with obstructive jaundice: report of a case and review of the literature.

J Gastrointest Cancer 2007 ;38(1):28-31

Department of Hematology-Oncology, University of Connecticut Health Center, Farmington, CT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12029-008-9012-4DOI Listing
February 2009

Myeloid sarcoma presenting with acute renal failure and bilateral ureteral obstruction: a case report and review of the literature.

Am J Med Sci 2007 Aug;334(2):136-8

Department of Medicine, Sinai-Grace Hospital/Wayne State University, Detroit, Michigan 48334, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S000296291532509
Publisher Site
http://dx.doi.org/10.1097/MAJ.0b013e31812e978bDOI Listing
August 2007

A rare case of postinfectious glomerulonephritis caused by pneumococcus in an adult patient.

J Nephrol 2007 Jan-Feb;20(1):99-102

Department of Internal Medicine, Sinai-Grace Hospital, Detroit Medical Center, Wayne State University, Detroit, Michigan - USA.

View Article

Download full-text PDF

Source
July 2007

Chemotherapy-induced thymus hyperplasia can mimic tumor recurrence.

Breast J 2006 Jul-Aug;12(4):381-2

Department of Hematology Oncology, Providence Hospital and Medical Center, Southfield, Michigan, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/j.1075-122X.2006.00283.x
Publisher Site
http://dx.doi.org/10.1111/j.1075-122X.2006.00283.xDOI Listing
August 2006

Multifaceted role of Rho proteins in angiogenesis.

J Mammary Gland Biol Neoplasia 2005 Oct;10(4):291-8

Breast and Ovarian Cancer Risk Evaluation Program, University of Michigan Comprehensive Cancer Center, 7217 CCGC, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0948, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10911-006-9002-8
Publisher Site
http://dx.doi.org/10.1007/s10911-006-9002-8DOI Listing
October 2005